Atlas Trials

Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT07269639 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07269639
Sponsor
Seoul National University Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Large B-Cell Lymphoma (LBCL)
Start date
2026-01-01
Primary completion
2027-12-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.